FDA Inspection 1302062 — Aaron Ahearn
The FDA completed an inspection of Aaron Ahearn on February 4, 2026 in Los Angeles, CA. The inspection was classified NAI (No Action Indicated — no objectionable conditions were found). Product area: Devices.
Inspection Details
- Classification
- No Action Indicated (NAI) (NAI)
- End Date
- February 4, 2026
- Fiscal Year
- 2026
- Product Type
- Devices
- Project Area
- Bioresearch Monitoring
- Location
- Los Angeles, CA (United States)
Additional Details
Clinical Investigator (CI)